I’ve just found this news item on the internet about the Diabetes Monitoring Forum and one of its early successes. It seems that the DMF developed important new patient guidelines in the form of an advice card.
New Patient Guidelines Developed to Help Prevent Deaths From Diabetic Ketoacidosis
Diabetic ketoacidosis (DKA), a complication of diabetes resulting from insufficient insulin, can lead to coma and eventually death if it is not controlled. Minimising the likelihood of developing DKA is the first priority for the newly set up Diabetes Monitoring Forum, which has created new blood ketone monitoring advice for patients.
Today at the annual Professional Conference of Diabetes UK in Glasgow the Forum presented the evidence-base supporting the development of this new advice card.
The catalyst for the card’s creation stems from a recent advance in monitoring technology, which enables patients to measure both blood glucose and blood ketones using the same device.
The new advice card was necessitated (is this really a word?) by a recent advance, whereby people with diabetes can now monitor blood ketones, with a meter that measures both blood glucose and blood ketones, the Optium Meter from MediSense, a division of Abbott Laboratories.
The new advice card, which will be made available through the healthcare team and launched later this year, provides a simple set of instructions for people with diabetes. It helps them to adjust their treatment according to the level of blood ketones detected by their monitor. Previously, the only way for people to keep a check on diabetic ketoacidosis was by measuring urinary ketones.
Read on here for more information about the new patient guidelines developed by the DMF, which I think I should point out is not an advert for the new Optium Meter from MediSense, a division of Abbott Laboratories. No really, it isn’t…
As for the DMF “…part of the overall mission of the Diabetes Monitoring Forum, which is to optimise the role of blood glucose and blood ketone monitoring in the management of diabetes. The Forum aims to achieve this by creating and evaluating advice and practical materials for both people with diabetes and healthcare professionals.”
To find out more you were asked to contact Dr Neil Bindemann at PRiMED Communications (PRiMED changed its name to Innervate on 16 March 2004).
All in all, I think it’s apposite to finish once again with the immortal words of Jim Thomson “… ask yourself one question…What does this person, or this organisation, have to gain from taking this position? All may become marginally clearer. Jim.”